Compare EL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EL | UTHR |
|---|---|---|
| Founded | 1946 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4B | 25.1B |
| IPO Year | 2007 | 1999 |
| Metric | EL | UTHR |
|---|---|---|
| Price | $85.47 | $562.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 14 |
| Target Price | $97.60 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 3.5M | 357.6K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | 0.82 | ★ 5.82 |
| Revenue | ★ $14,326,000,000.00 | $1,483,300,000.00 |
| Revenue This Year | $7.51 | $6.39 |
| Revenue Next Year | $4.08 | $14.18 |
| P/E Ratio | $103.96 | ★ $98.27 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $62.03 | $272.18 |
| 52 Week High | $121.64 | $609.35 |
| Indicator | EL | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 48.29 |
| Support Level | $84.34 | $560.16 |
| Resistance Level | $93.70 | $600.77 |
| Average True Range (ATR) | 3.07 | 15.44 |
| MACD | 1.57 | -2.26 |
| Stochastic Oscillator | 81.32 | 7.05 |
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%). Top-selling brands include Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.